WallStreetZenWallStreetZen

NASDAQ: BIOR
Biora Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for BIOR

Based on 1 analyst offering 12 month price targets for Biora Therapeutics Inc.
Min Forecast
$4.00+2.04%
Avg Forecast
$4.00+2.04%
Max Forecast
$4.00+2.04%

Should I buy or sell BIOR stock?

Based on 1 analyst offering ratings for Biora Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BIOR stock forecasts and price targets.

BIOR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
BTIG
Top 15%
86
Strong BuyAssumes$4.00+2.04%2022-05-03

1 of 1

Forecast return on equity

Is BIOR forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is BIOR forecast to generate an efficient return on assets?
Company
-5.84%
Industry
12.32%
BIOR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BIOR earnings per share forecast

What is BIOR's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.43
Avg 2 year Forecast
-$0.46
Avg 3 year Forecast
-$0.48

BIOR revenue forecast

What is BIOR's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$1.9M+155.1%
Avg 2 year Forecast
$12.9M+1,676.86%
Avg 3 year Forecast
$12.9M+1,676.86%
BIOR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BIOR revenue growth forecast

How is BIOR forecast to perform vs Biotechnology companies and vs the US market?
Company
256.32%
Industry
64.15%
Market
11.02%
BIOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIOR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BIOR$3.92$4.00+2.04%Strong Buy
FWBI$5.16$13.50+161.63%Strong Buy
NMTR$2.31$14.00+506.06%Buy
CYCN$0.68$9.00+1,217.72%Strong Buy
SABS$0.69$3.50+407.25%Strong Buy

Biora Therapeutics Stock Forecast FAQ

Is Biora Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BIOR) stock is to Strong Buy BIOR stock.

Out of 1 analyst, 1 (100%) are recommending BIOR as a Strong Buy, 0 (0%) are recommending BIOR as a Buy, 0 (0%) are recommending BIOR as a Hold, 0 (0%) are recommending BIOR as a Sell, and 0 (0%) are recommending BIOR as a Strong Sell.

If you're new to stock investing, here's how to buy Biora Therapeutics stock.

What is BIOR's earnings growth forecast for 2023-2025?

(NASDAQ: BIOR) Biora Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 27.25%.

Biora Therapeutics's earnings in 2023 is -$117,308,000.On average, 1 Wall Street analyst forecast BIOR's earnings for 2023 to be -$3,275,100, with the lowest BIOR earnings forecast at -$3,275,100, and the highest BIOR earnings forecast at -$3,275,100. On average, 1 Wall Street analyst forecast BIOR's earnings for 2024 to be -$3,503,596, with the lowest BIOR earnings forecast at -$3,503,596, and the highest BIOR earnings forecast at -$3,503,596.

In 2025, BIOR is forecast to generate -$3,655,926 in earnings, with the lowest earnings forecast at -$3,655,926 and the highest earnings forecast at -$3,655,926.

What is BIOR's revenue growth forecast for 2023-2028?

(NASDAQ: BIOR) Biora Therapeutics's forecast annual revenue growth rate of 256.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.15%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 11.02%.

Biora Therapeutics's revenue in 2023 is $726,000.On average, 1 Wall Street analysts forecast BIOR's revenue for 2023 to be $14,105,780, with the lowest BIOR revenue forecast at $14,105,780, and the highest BIOR revenue forecast at $14,105,780. On average, 1 Wall Street analysts forecast BIOR's revenue for 2027 to be $98,253,005, with the lowest BIOR revenue forecast at $98,253,005, and the highest BIOR revenue forecast at $98,253,005.

In 2028, BIOR is forecast to generate $98,253,005 in revenue, with the lowest revenue forecast at $98,253,005 and the highest revenue forecast at $98,253,005.

What is BIOR's forecast return on assets (ROA) for 2023-2025?

(NASDAQ: BIOR) forecast ROA is -5.84%, which is lower than the forecast US Biotechnology industry average of 12.32%.

What is BIOR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BIOR price target, the average BIOR price target is $4.00, with the highest BIOR stock price forecast at $4.00 and the lowest BIOR stock price forecast at $4.00.

The Wall Street analyst predicted that Biora Therapeutics's share price could reach $4.00 by May 3, 2023. The average Biora Therapeutics stock price prediction forecasts a potential upside of 2.04% from the current BIOR share price of $3.92.

What is BIOR's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: BIOR) Biora Therapeutics's current Earnings Per Share (EPS) is -$14.50. On average, analysts forecast that BIOR's EPS will be -$0.43 for 2023, with the lowest EPS forecast at -$0.43, and the highest EPS forecast at -$0.43. On average, analysts forecast that BIOR's EPS will be -$0.46 for 2024, with the lowest EPS forecast at -$0.46, and the highest EPS forecast at -$0.46. In 2025, BIOR's EPS is forecast to hit -$0.48 (min: -$0.48, max: -$0.48).

What is BIOR's forecast return on equity (ROE) for 2023-2025?

(NASDAQ: BIOR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.